Answers are grounded in this paper and cite their sources.
Bristol-Myers Squibb and Company announced October 16 that FDA approved the marketing of ixabepilone for the treatment of certain types of metastatic or locally advanced breast cancer. The drug product is being sold under the brand name Ixempra Kit. Ixabepilone is an epothilone, a cytoxic compound
No takes yet. Share an insight, caveat, or question.
Cheryl A. Thompson (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: